| Baseline | Treatment | Before vs. After Treatment Pairwise Comparison (p value) | |||||
---|---|---|---|---|---|---|---|---|
 | Active | Sham | p | Active | Sham | p | Active | Sham |
LV Mass | 106.1 ± 28.9 | 108.3 ± 23.6 | 0.86 | 111.34 ± 39.8 | 118.4 ± 25.0 | 0.66 | 0.36 | 0.18 |
LV Mass/BSA | 52.2 ± 11.4 | 49.3 ± 7.9 | 0.54 | 56.6 ± 18.4 | 69.9 ± 32.2 | 0.98 | 0.38 | 0.15 |
RVEDV | 161.1 ± 28.6 | 171.8 ± 35.4 | 0.49 | 165.8 ± 38.1 | 181.6 ± 54.2 | 0.48 | 0.40 | 0.40 |
RVEDV/BSA | 79.7 ± 13.0 | 79.1 ± 15.8 | 0.93 | 81.7 ± 79.4 | 82.6 ± 22.5 | 0.92 | 0.45 | 0.53 |
LVEDV | 148.3 ± 32 | 158.3 ± 31.1 | 0.51 | 151.1 ± 30.5 | 163.4 ± 38.7 | 0.46 | 0.63 | 0.39 |
LVEDV/BSA | 73.0 ± 13.5 | 72.3 ± 9.6 | 0.88 | 74.7 ± 13.4 | 74.4 ± 14.2 | 0.96 | 0.47 | 0.57 |
RV EF | 58.9 ± 6.9 | 56.7 ± 9.0 | 0.57 | 55.5 ± 5.7 | 54.0 ± 11.4 | 0.80 | 0.26 | 0.43 |
LV EF | 68.9 ± 7.1 | 67.4 ± 8.2 | 0.69 | 71.5 ± 4.6 | 65.1 ± 7.5 | 0.04 | 0.34 | 0.31 |
MPR | 1.5 ± 0.5 | 2.0 ± 1.2 | 0.38 | 3.0 ± 1.3 | 2.5 ± 1.1 | 0.49 | 0.02 | 0.38 |
Change in CSA RCA, % | 14+8 | 20 ± 10 | 0.16 | 18 ± 15 | 15 ± 8 | 0.58 | 0.46 | 0.23 |